TGF-β1 prevents blood-brain barrier damage and hemorrhagic transformation after thrombolysis in rats

Experimental Neurology

Volumn 266, Issue , 2015, Pages 120-126

  Cai, Yingyuan ^a   Liu, Xinfeng ^b   Chen, Weixian ^a   Wang, Zhenzhen ^a   Xu, Gelin ^b   Zeng, Yanying ^a   Ma, Yuping ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Basement membrane; Blood brain barrier; Hemorrhagic transformation; Middle cerebral artery occlusion; Thrombolysis; Transforming growth factor beta1

Indexed keywords

ALTEPLASE; COLLAGEN TYPE 4; EVANS BLUE; GELATINASE A; GELATINASE B; LAMININ; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SODIUM CHLORIDE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER DAMAGE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRAVASATION; GELATIN ZYMOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE DAMAGE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT MODEL; THROMBOEMBOLISM; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ADVERSE EFFECTS; ANIMAL; BLOOD BRAIN BARRIER; CEREBRAL ARTERY DISEASE; DRUG EFFECTS; FIBRINOLYTIC THERAPY; INTRACRANIAL HEMORRHAGES; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; STROKE;

ANIMALS; BLOOD-BRAIN BARRIER; FIBRINOLYTIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL HEMORRHAGES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84924110689     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.02.013     Document Type: Article

References (34)

1. Abdullah W.Z., Idris S.Z., Bashkar S., Hassan R. Role of fibrinolytic markers in acute stroke. Singap. Med. J. 2009, 50:604-609.
2. Adibhatla R.M., Hatcher J.F. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol. Disord. Drug Targets 2008, 7:243-253.
3. Buga A.M., Scholz C.J., Kumar S., Herndon J.G., Alexandru D., Cojocaru G.R., Dandekar T., Popa-Wagner A. Identification of new therapeutic targets by genome-wide analysis of gene expression in the ipsilateral cortex of aged rats after stroke. PLoS One 2012, 7:e50985.
4. Buisson A., Lesne S., Docagne F., Ali C., Nicole O., MacKenzie E.T., Vivien D. Transforming growth factor-beta and ischemic brain injury. Cell. Mol. Neurobiol. 2003, 23:539-550.
5. Dai J., Losy F., Guinault A.M., Pages C., Anegon I., Desgranges P., Becquemin J.P., Allaire E. Overexpression of transforming growth factor-β1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation 2005, 112:1008-1015.
6. Dobolyi A., Vincze C., Pál G., Lovas G. The neuroprotective functions of transforming growth factor beta proteins. Int. J. Mol. Sci. 2012, 13:8219-8258.
7. Garcia-Yebenes I., Sobrado M., Zarruk J.G., Castellanos M., Ossa N.P., Davalos A., Serena J., Lizasoain I., Moro M.A. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke. Stroke 2011, 42:196-203.
8. Gasche Y., Fujimura M., Morita-Fujimura Y., Copin J.C., Kawase M., Massengale J., et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J. Cereb. Blood Flow Metab. 1999, 19:1020-1028.
9. Gidday J.M., Gasche Y.G., Copin J.C., Shah A.R., Perez R.S., Shapiro S.D., et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:558-568.
10. Gliem M., Mausberg A.K., Lee J.I., Simiantonakis I., van-Rooijen N., Hartung H.P., Jander S. Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann. Neurol. 2012, 71:743-752.
11. Hamann G.F., Liebetrau M., Martens H., Burggraf D., Kloss C.U., Bültemeier G., Wunderlich N., Jäger G., Pfefferkorn T. Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. J. Cereb. Blood Flow Metab. 2002, 22:526-533.
12. Hu C.P., Dandapat A., Liu Y., Hermonat P.L., Mehta J.L. Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF-beta1 delivered by AAV in mouse cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:1833-1838.
13. Klass B.R., Grobbelaar A.O., Rolfe K.J. Transforming growth factor β1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance. Postgrad. Med. J. 2009, 85:9-14.
14. Latour L.L., Kang D.W., Ezzeddine M.A., Chalela J.A., Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann. Neurol. 2004, 56:468-477.
15. Li M., Zhang Z., Sun W., Koehler R.C., Huang J. 17β-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia. Neurobiol. Dis. 2011, 44:277-283.
16. Liu R., Liu Q., He S., Simpkins J.W., Yang S.H. Combination therapy of 17β-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. J. Pharmacol. Exp. Ther. 2010, 332:1006-1012.
17. Liu J., Jin X., Liu K.J., Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J. Neurosci. 2012, 32:3044-3057.
18. Montaner J., Molina C.A., Monasterio J., Abilleira S., Arenillas J.F., Ribó M., et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107:598-603.
19. Morancho A., Rosell A., García-Bonilla L., Montaner J. Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment?. Ann. N. Y. Acad. Sci. 2010, 1207:123-133.
20. Ogawa K., Chen F., Kuang C., Chen Y. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-β is mediated by a nuclear factor-κb site. Biochem. J. 2004, 381:413-422.
21. Popa-Wagner A., Pirici D., Petcu E.B., Mogoanta L., Buga A.M., Rosen C.L., Leon R., Huber J. Pathophysiology of the vascular wall and its relevance for cerebrovascular disorders in aged rodents. Curr. Neurovasc. Res. 2010, 7:251-267.
22. Ribo M., Montaner J., Molina C.A., Arenillas J.F., Santamarina E., Quintana M., Alvarez-Sabin J. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004, 35:2123-2127.
23. Ronaldson P.T., DeMarco K.M., Sanchez-Covarrubias L., Solinsky C.M., Davis T.P. Transforming growth factor-β signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J. Cereb. Blood Flow Metab. 2009, 29:1084-1098.
24. Rosell A., Cuadrado E., Ortega-Aznar A., Hernandez-Guillamon M., Lo E.H., Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type iv collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008, 39:1121-1126.
25. Shatos M.A., Doherty J.M., Penar P.L., Sobel B.E. Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. Circulation 1996, 94:636-642.
26. Simard J.M., Geng Z., Silver F.L., Sheth K.N., Kimberly W.T., Stern B.J., Colucci M., Gerzanich V. Does inhibiting Sur1 complement rt-PA in cerebral ischemia?. Ann. N. Y. Acad. Sci. 2012, 1268:95-107.
27. Tjärnlund-Wolf A., Brogren H., Lo E.H., Wang X. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke 2012, 43:2833-2839.
28. Vaday G.G., Schor H., Rahat M.A., Lahat N., Lider O. Transforming growth factor-beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes. J. Leukoc. Biol. 2001, 69:613-621.
29. Vivien D., Ali C. Transforming growth factor-β signalling in brain disorders. Cytokine Growth Factor Rev. 2006, 17:121-128.
30. Wang C.X., Shuaib A. Critical role of microvasculature basal lamina in ischemic brain injury. Prog. Neurobiol. 2007, 83:140-148.
31. Wang X., Tsuji K., Lee S.R., Ning M.M., Furie K.L., Buchan A.M., et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004, 35:2726-2730.
32. Warach S., Latour L.L. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004, 35:2659-2661.
33. Yamashita T., Kamiya T., Deguchi K., Inaba T., Zhang H., Shang J., et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J. Cereb. Blood Flow Metab. 2009, 29:715-725.
34. Yurchenco P.D., Schittny J.C. Molecular architecture of basement membranes. FASEB J. 1990, 4:1577-1590.